Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors

Matthew F. Buas, Haiwei Gu, Danijel Djukovic, Jiangjiang Zhu, Charles W. Drescher, Nicole Urban, Daniel Raftery, Christopher I. Li

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective Serous ovarian carcinoma (OC) represents a leading cause of cancer-related death among U.S. women. Non-invasive tools have recently emerged for discriminating benign from malignant ovarian masses, but evaluation remains ongoing, without widespread implementation. In the last decade, metabolomics has matured into a new avenue for cancer biomarker development. Here, we sought to identify novel plasma metabolite biomarkers to distinguish serous ovarian carcinoma and benign serous ovarian tumor. Methods Using liquid chromatography-mass spectrometry, we conducted global and targeted metabolite profiling of plasma isolated at the time of surgery from 50 serous OC cases and 50 serous benign controls. Results Global lipidomics analysis identified 34 metabolites (of 372 assessed) differing significantly (P < 0.05) between cases and controls in both training and testing sets, with 17 candidates satisfying FDR q < 0.05, and two reaching Bonferroni significance. Targeted profiling of ~ 150 aqueous metabolites identified a single amino acid, alanine, as differentially abundant (P < 0.05). A multivariate classification model built using the top four lipid metabolites achieved an estimated AUC of 0.85 (SD = 0.07) based on Monte Carlo cross validation. Evaluation of a hybrid model incorporating both CA125 and lipid metabolites was suggestive of increased classification accuracy (AUC = 0.91, SD = 0.05) relative to CA125 alone (AUC = 0.87, SD = 0.07), particularly at high fixed levels of sensitivity, without reaching significance. Conclusions Our results provide insight into metabolic changes potentially correlated with the presence of serous OC versus benign ovarian tumor and suggest that plasma metabolites may help differentiate these two conditions.

Original languageEnglish (US)
Pages (from-to)138-144
Number of pages7
JournalGynecologic Oncology
Volume140
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Biomarkers
Area Under Curve
Carcinoma
Neoplasms
Lipids
Metabolomics
Tumor Biomarkers
Liquid Chromatography
Alanine
Mass Spectrometry
Amino Acids

Keywords

  • Lipidomics
  • Metabolomics
  • Molecular diagnostics
  • Plasma biomarkers
  • Serous ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. / Buas, Matthew F.; Gu, Haiwei; Djukovic, Danijel; Zhu, Jiangjiang; Drescher, Charles W.; Urban, Nicole; Raftery, Daniel; Li, Christopher I.

In: Gynecologic Oncology, Vol. 140, No. 1, 01.01.2016, p. 138-144.

Research output: Contribution to journalArticle

Buas, Matthew F. ; Gu, Haiwei ; Djukovic, Danijel ; Zhu, Jiangjiang ; Drescher, Charles W. ; Urban, Nicole ; Raftery, Daniel ; Li, Christopher I. / Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. In: Gynecologic Oncology. 2016 ; Vol. 140, No. 1. pp. 138-144.
@article{7735f7ffdb88497186856af3d1b400d5,
title = "Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors",
abstract = "Objective Serous ovarian carcinoma (OC) represents a leading cause of cancer-related death among U.S. women. Non-invasive tools have recently emerged for discriminating benign from malignant ovarian masses, but evaluation remains ongoing, without widespread implementation. In the last decade, metabolomics has matured into a new avenue for cancer biomarker development. Here, we sought to identify novel plasma metabolite biomarkers to distinguish serous ovarian carcinoma and benign serous ovarian tumor. Methods Using liquid chromatography-mass spectrometry, we conducted global and targeted metabolite profiling of plasma isolated at the time of surgery from 50 serous OC cases and 50 serous benign controls. Results Global lipidomics analysis identified 34 metabolites (of 372 assessed) differing significantly (P < 0.05) between cases and controls in both training and testing sets, with 17 candidates satisfying FDR q < 0.05, and two reaching Bonferroni significance. Targeted profiling of ~ 150 aqueous metabolites identified a single amino acid, alanine, as differentially abundant (P < 0.05). A multivariate classification model built using the top four lipid metabolites achieved an estimated AUC of 0.85 (SD = 0.07) based on Monte Carlo cross validation. Evaluation of a hybrid model incorporating both CA125 and lipid metabolites was suggestive of increased classification accuracy (AUC = 0.91, SD = 0.05) relative to CA125 alone (AUC = 0.87, SD = 0.07), particularly at high fixed levels of sensitivity, without reaching significance. Conclusions Our results provide insight into metabolic changes potentially correlated with the presence of serous OC versus benign ovarian tumor and suggest that plasma metabolites may help differentiate these two conditions.",
keywords = "Lipidomics, Metabolomics, Molecular diagnostics, Plasma biomarkers, Serous ovarian cancer",
author = "Buas, {Matthew F.} and Haiwei Gu and Danijel Djukovic and Jiangjiang Zhu and Drescher, {Charles W.} and Nicole Urban and Daniel Raftery and Li, {Christopher I.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2015.10.021",
language = "English (US)",
volume = "140",
pages = "138--144",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors

AU - Buas, Matthew F.

AU - Gu, Haiwei

AU - Djukovic, Danijel

AU - Zhu, Jiangjiang

AU - Drescher, Charles W.

AU - Urban, Nicole

AU - Raftery, Daniel

AU - Li, Christopher I.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective Serous ovarian carcinoma (OC) represents a leading cause of cancer-related death among U.S. women. Non-invasive tools have recently emerged for discriminating benign from malignant ovarian masses, but evaluation remains ongoing, without widespread implementation. In the last decade, metabolomics has matured into a new avenue for cancer biomarker development. Here, we sought to identify novel plasma metabolite biomarkers to distinguish serous ovarian carcinoma and benign serous ovarian tumor. Methods Using liquid chromatography-mass spectrometry, we conducted global and targeted metabolite profiling of plasma isolated at the time of surgery from 50 serous OC cases and 50 serous benign controls. Results Global lipidomics analysis identified 34 metabolites (of 372 assessed) differing significantly (P < 0.05) between cases and controls in both training and testing sets, with 17 candidates satisfying FDR q < 0.05, and two reaching Bonferroni significance. Targeted profiling of ~ 150 aqueous metabolites identified a single amino acid, alanine, as differentially abundant (P < 0.05). A multivariate classification model built using the top four lipid metabolites achieved an estimated AUC of 0.85 (SD = 0.07) based on Monte Carlo cross validation. Evaluation of a hybrid model incorporating both CA125 and lipid metabolites was suggestive of increased classification accuracy (AUC = 0.91, SD = 0.05) relative to CA125 alone (AUC = 0.87, SD = 0.07), particularly at high fixed levels of sensitivity, without reaching significance. Conclusions Our results provide insight into metabolic changes potentially correlated with the presence of serous OC versus benign ovarian tumor and suggest that plasma metabolites may help differentiate these two conditions.

AB - Objective Serous ovarian carcinoma (OC) represents a leading cause of cancer-related death among U.S. women. Non-invasive tools have recently emerged for discriminating benign from malignant ovarian masses, but evaluation remains ongoing, without widespread implementation. In the last decade, metabolomics has matured into a new avenue for cancer biomarker development. Here, we sought to identify novel plasma metabolite biomarkers to distinguish serous ovarian carcinoma and benign serous ovarian tumor. Methods Using liquid chromatography-mass spectrometry, we conducted global and targeted metabolite profiling of plasma isolated at the time of surgery from 50 serous OC cases and 50 serous benign controls. Results Global lipidomics analysis identified 34 metabolites (of 372 assessed) differing significantly (P < 0.05) between cases and controls in both training and testing sets, with 17 candidates satisfying FDR q < 0.05, and two reaching Bonferroni significance. Targeted profiling of ~ 150 aqueous metabolites identified a single amino acid, alanine, as differentially abundant (P < 0.05). A multivariate classification model built using the top four lipid metabolites achieved an estimated AUC of 0.85 (SD = 0.07) based on Monte Carlo cross validation. Evaluation of a hybrid model incorporating both CA125 and lipid metabolites was suggestive of increased classification accuracy (AUC = 0.91, SD = 0.05) relative to CA125 alone (AUC = 0.87, SD = 0.07), particularly at high fixed levels of sensitivity, without reaching significance. Conclusions Our results provide insight into metabolic changes potentially correlated with the presence of serous OC versus benign ovarian tumor and suggest that plasma metabolites may help differentiate these two conditions.

KW - Lipidomics

KW - Metabolomics

KW - Molecular diagnostics

KW - Plasma biomarkers

KW - Serous ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=84951754549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951754549&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2015.10.021

DO - 10.1016/j.ygyno.2015.10.021

M3 - Article

VL - 140

SP - 138

EP - 144

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -